In the press

James Carthew explains why ‘no’ to Saba in Investment Week

Biotech trusts top performance charts in February

James Carthew explains why he will reject Saba’s EWIT proposals in Linus Uhlig’s article:

“There are many reasons for this but chief of them is Saba’s reluctance to spell out exactly what it intends to do with the company if it manages to seize control of it, as it will do if its proposals succeed. The independence of boards is a fundamental, non-negotiable, tenet of the UK investment company sector,”

Read the article here